- Naranj Research Desk
- 🇸🇦 Saudi Stock Market
- 🇺🇸 USA Stock Market
ALNY — NASDAQ —
Current RSI of this stock is 71.21, which indicates the strength of buyers.
Increasing ADX value above 20, indicated the strength of the trend, thereby uptrending ADX confirms the bullish or bearish supportive decisions. Along with the rising ADX, and the +DI is above (or crossing) -DI, indicates the long trades should be favoured.
The short length exponential moving average (10 EMA) has crossed the long length exponential moving average (20 EMA) from the below, generates bullish signal. Last day’s candle has closed above all these moving averages. This suggests buyers are taking interest in this stock.
Based on our swing trade signals for Nasdaq 100 stocks, Alnylam Pharmaceuticals stock price target will be USD 305 - USD 310 in the next 12-14 trading sessions.
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company that focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of hereditary transthyretin-mediated amyloidosis in adults, AMVUTTRA for hATTR amyloidosis with polyneuropathy in adults, GIVLAARI for acute hepatic porphyria, and OXLUMO for primary hyperoxaluria type 1. The company also develops patisiran for ATTR amyloidosis with cardiomyopathy, cemdisiran for complement-mediated diseases, Belcesiran for alpha-1 liver disease, Elebsiran for chronic HBV infection, Zilebesiran for hypertension, ALN-APP for Alzheimer’s disease and cerebral amyloid angiopathy, and ALN-HSD for NASH. The company has strategic collaborations with Regeneron Pharmaceuticals and Roche to develop RNAi therapeutics for various diseases, and has license and collaboration agreements with Novartis AG, Vir Biotechnology, Dicerna Pharmaceuticals, Ionis Pharmaceuticals, and PeptiDream. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
ALNY — NASDAQ —
Current RSI of this stock is 71.21, which indicates the strength of buyers.
Increasing ADX value above 20, indicated the strength of the trend, thereby uptrending ADX confirms the bullish or bearish supportive decisions. Along with the rising ADX, and the +DI is above (or crossing) -DI, indicates the long trades should be favoured.
The short length exponential moving average (10 EMA) has crossed the long length exponential moving average (20 EMA) from the below, generates bullish signal. Last day’s candle has closed above all these moving averages. This suggests buyers are taking interest in this stock.
Based on our swing trade signals for Nasdaq 100 stocks, Alnylam Pharmaceuticals stock price target will be USD 305 - USD 310 in the next 12-14 trading sessions.
Arijit Banerjee CMT CFTe is a seasoned expert in the financial industry, boasting decades of experience in trading, investment, and wealth management. As the founder and chief strategist of Naranj Capital, he’s built a reputation for providing insightful research analysis to guide investment decisions.
Arijit’s credentials are impressive, holding both the Chartered Market Technician (CMT) and Certified Financial Technician (CFTe) designations. These certifications demonstrate his expertise in technical analysis and financial markets.
Through Naranj Capital, Arijit shares his market insights and research analysis, offering actionable advice for investors. His work is featured on platforms like TradingView, where he publishes detailed analysis and recommendations.
If you’re interested in learning more about Arijit’s work or Naranj Capital’s services, you can reach out to them directly through their website
